Evidence map›Paper›PMID 40276882›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025

Seroprevalence against measles, Austria, stratified by birth years 1922 to 2024.

David N Springer, Christian Borsodi, Jeremy V Camp, Monika Redlberger-Fritz, Heidemarie Holzmann, Michael Kundi, Judith H Aberle, Karin Stiasny, Lukas Weseslindtner

Erratum issuedAbstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Measles seroprevalence by birth cohort across the lifespan: a population-based, cross-sectional serosurvey in British Columbia, Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Sustaining successes and addressing challenges to vaccination - a continued public health mission.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

David N SpringerCenter for Virology, Medical University of Vienna, Vienna, Austria.
Christian BorsodiCenter for Virology, Medical University of Vienna, Vienna, Austria.
Jeremy V CampCenter for Virology, Medical University of Vienna, Vienna, Austria.
Monika Redlberger-FritzCenter for Virology, Medical University of Vienna, Vienna, Austria.
Heidemarie HolzmannCenter for Virology, Medical University of Vienna, Vienna, Austria.
Michael KundiCenter for Public Health, Medical University of Vienna, Vienna, Austria.
Judith H AberleCenter for Virology, Medical University of Vienna, Vienna, Austria.
Karin StiasnyCenter for Virology, Medical University of Vienna, Vienna, Austria.
Lukas WeseslindtnerCenter for Virology, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundVaccination programmes initiated in the early 1970s reduced the incidence of measles in Austria, which resulted in the interruption of endemic measles virus (MeV) circulation and the achievement of elimination status in 2018. However, large outbreaks occurred in 2023 and 2024.AimBy assessing MeV-specific IgG antibody levels, we analysed if immunity recently declined due to the COVID-19 pandemic, vaccine-induced immunity waned over long term or immunity gaps already pre-existed in the population.MethodsWe determined anti-MeV antibody levels in a retrospective dataset of 56,360 diagnostic samples (from 50,754 individuals) collected 2010-2024 and correlated antibody cutoffs to titres from a live-virus neutralisation test.ResultsIndividuals born before 1970 (n = 15,007) had antibody levels > 3,000 IU/L, persisting into higher age, and < 2% (n = 300) of them were seronegative. In contrast, individuals born after 1990 (n = 12,778) displayed seronegativity rates of 13-20% and lower median antibody concentrations in seropositive individuals (449-773 IU/L). In these individuals, antibody levels decreased noticeably between the ages of 2 and 10 years but remained stable between those aged 10 and 30 years. There was no significant difference in seronegativity rates at the age of 12-24 months in children born 2016-2019 and 2020-2022 (the years of the COVID-19 pandemic).ConclusionIn Austria, there are significant immunity gaps in individuals born after 1970, which pre-existed before the COVID-19 pandemic. Thus, young and middle-aged populations not immune against measles should be vaccinated to counteract a further decline of immunity at the population level and prevent outbreaks whenever MeV is imported.

Indexed as

Antibodies, ViralCOVID-19MeaslesMeasles VaccineMeasles virusAdolescentAdultAgedAustriaChildChild, PreschoolFemaleHumansImmunoglobulin GInfantMaleAntibodies, ViralImmunoglobulin GMeasles VaccineantibodyAustriameaslesmeasles–mumps–rubella (MMR) vaccineseroprevalencevaccines and immunisationwaning

Identifiers

PMID40276882
PMCPMC12023729

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.